Groundbreaking Clinical Trial Results for LIBERTY System
Microbot Medical Inc. has recently unveiled impressive findings regarding its LIBERTY Endovascular Robotic System. Achieving a remarkable 100% success rate in robotic navigation, the results from this clinical trial highlight the innovative technology and its potential to change the landscape of endovascular procedures.
Study Overview
The pivotal ACCESS-PVI study was shared by Microbot Medical at a notable medical conference, where key data pointed to the efficacy and safety of the LIBERTY system in robotic endovascular surgeries. Carrying out tests at three premier medical facilities, the results underscored the system's potential to transform patient outcomes significantly.
Key Findings from the ACCESS-PVI Study
Robotic navigation was successfully executed in every instance, with the study involving 20 cases. This achievement exceeded expectations and met the primary objective of the trial. Highlighting the effectiveness of the LIBERTY system, here are some key figures from the study:
- Every case reached successful robotic navigation, achieving a perfect score of 100% success.
- No adverse device events were recorded throughout the follow-up, demonstrating the system's reliability.
- Notably, the average reduction in radiation exposure was an impressive 92%, emphasizing the system's safety.
- The average navigation time to target was a swift 3 minutes, showcasing efficiency in procedures.
- Participating doctors expressed high satisfaction levels, with a flawless performance rating reported.
Statements from Company Leadership
Harel Gadot, Chairman, CEO, and President of Microbot Medical, shared his enthusiasm for the trial results. "The ACCESS-PVI data reflects our team's dedication to the LIBERTY system. We are eager to transition into a commercial phase and are confident in a positive reception market-wide,” he said. This sentiment was echoed by Dr. Juan Diaz-Cartelle, the Chief Medical Officer, who emphasized the ease of use and quick learning curve associated with the system.
What Makes LIBERTY Unique?
The LIBERTY system is pioneering world-first single-use, fully disposable robotic technology, aiming to break down barriers previously encountered in accessing advanced robotic systems. Its innovative approach is designed to enhance medical service delivery and improve healthcare outcomes for patients globally. Upon receiving FDA clearance, the LIBERTY system is set to make significant waves within the medical community.
About Microbot Medical
Microbot Medical Inc. (NASDAQ: MBOT) is on the verge of launching an innovative device that could drastically improve the endovascular process. As a pre-commercial stage company, they focus on addressing challenges faced by healthcare providers and patients alike, committed to facilitating advancements in medical technology.
Frequently Asked Questions
What is the significance of the LIBERTY Endovascular Robotic System?
The LIBERTY system represents a significant advancement in endovascular procedures, showcasing a 100% success rate in robotic navigation during trials.
Who presented the ACCESS-PVI study results?
The results were presented by Dr. Francois Cornelis during the Society of Interventional Radiology annual meeting, highlighting the study's critical findings.
How does the LIBERTY system reduce radiation exposure?
The advanced design and technology of the LIBERTY system have led to a significant reduction in radiation exposure for both patients and operators.
What feedback has the LIBERTY system received from physicians?
Physicians reported a 100% satisfaction rate with the LIBERTY system, noting its intuitive operation and effectiveness during procedures.
When is the LIBERTY system expected to launch?
The LIBERTY system is currently seeking FDA clearance, after which it is anticipated to be available in the market.
